NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: M1 Kliniken AG's 2025 Financial Performance and Strategic Outlook
TL;DR
M1 Kliniken AG's strategic sale of HAEMATO Pharm and focus on medical aesthetics positions investors for advantage with 11% EBIT growth and expanding market leadership.
M1 Kliniken achieved profitability through efficiency measures, capacity expansion, and optimized processes, resulting in 6.7% revenue growth and improved EBIT margins across segments.
M1 Kliniken's expansion of medical aesthetic services provides accessible, physician-performed treatments at leading prices, improving patient access to quality care globally.
M1 Kliniken operates 58 clinics across ten countries and aims to become the world's leading aesthetic medicine brand by 2029 through strategic vertical integration.
Found this article helpful?
Share it with your network and spread the knowledge!
The company achieved group revenue of EUR 274.3 million (up 6.7%), EBITDA of EUR 28.2 million (up 9%), EBIT of EUR 24.5 million (up 11%), and earnings per share of EUR 0.86.
The Beauty segment showed strong growth with revenue up 9.5% to EUR 77.8 million and EBIT up 29.7% to EUR 21.1 million, while the Trading segment saw revenue growth of 6% to EUR 196.5 million but EBIT declined by 41.4% to EUR 3.4 million.
The company announced that its 85% subsidiary HAEMATO AG has signed an agreement to sell HAEMATO Pharm GmbH to the PHOENIX group, subject to antitrust approvals, as part of its strategy to focus on medical aesthetics.
The company aims to expand its clinic network and expects revenue to reach between EUR 200-300 million by 2029 with a sustainable EBIT margin of at least 20%, positioning M1 Med Beauty as the world's leading brand for aesthetic medicine.
Efficiency gains through optimized processes, higher utilization of medical capacities, and a targeted pricing strategy that expanded market share without compromising margin quality drove the improved profits.
The company positions itself as the leading provider of high-quality aesthetic medicine at the best price, operating as a vertically integrated pure-play provider of medical aesthetics services.
The Group currently operates 58 clinics in ten countries under the M1 Med Beauty brand, with all treatments performed exclusively by qualified physicians adhering to uniform, high medical standards.
The group EBIT margin improved to 8.9% from 8.6% in the previous year, while the Beauty segment EBIT margin increased significantly to 27.1% from 22.9%.
Curated from NewMediaWire
